Side Effects of Anti-PD-(L)-1 and Anti CTLA-A4 in the Non Small Cells Lung Cancer

Cliniques universitaires Saint-Luc- Université Catholique de Louvain80 enrolled

Overview

The immune-related adverse events (irAEs) linked to the important activation of the immune system by new immunotherapy treatments in patients affected by Non-small-cell lung carcinoma (NSCLC) have not received a lot of systematic study or been monitored over time outside of clinical trials. This study aims to verify, on the basis of the data collected in a prospective and retrospective manner, that the side-effects due of anti-PD-(L)-1 or anti-CTLA-4 treatments observed in the target population of the controlled clinical trials are the same as in the general clinical population.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma, Non-Small-Cell Lung Drug-Related Side Effects and Adverse Reactions

Interventions

Consultation of the patient's medical files at the hospitalOTHER

Eligibility

Sex: ALLMin age: 20 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Any patient with NSCLC treated in Cliniques Universitaires Saint-Luc with immunotherapy in first or second line. Exclusion Criteria: * The refusal to sign the consent.

Outcomes

Primary Outcomes

Census and monitor of the side-effects due to the immunotherapy treatment.

Census of the side-effect type, severity according to the CTCAE and monitoring the side-effect's development.

Time frame: Through study completion, an average of 20 months.